These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23583730)

  • 1. (pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes.
    Irwin N; Frizelle P; O'Harte FP; Flatt PR
    Biochim Biophys Acta; 2013 Aug; 1830(8):4009-16. PubMed ID: 23583730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N; Hunter K; Montgomery IA; Flatt PR
    Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.
    Irwin N; Frizelle P; Montgomery IA; Moffett RC; O'Harte FPM; Flatt PR
    Diabetologia; 2012 Oct; 55(10):2747-2758. PubMed ID: 22814764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N; Montgomery IA; Moffett RC; Flatt PR
    Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes.
    Irwin N; Montgomery IA; O'Harte FP; Frizelle P; Flatt PR
    Int J Obes (Lond); 2013 Aug; 37(8):1058-63. PubMed ID: 23164696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice.
    Irwin N; Frizelle P; O'Harte FP; Flatt PR
    J Endocrinol; 2013 Jan; 216(1):53-9. PubMed ID: 23055535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
    Irwin N; Pathak V; Flatt PR
    Diabetes; 2015 Aug; 64(8):2996-3009. PubMed ID: 25883113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression.
    Montgomery IA; Irwin N; Flatt PR
    Horm Metab Res; 2013 Jun; 45(6):471-3. PubMed ID: 23315994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice.
    Irwin N; Montgomery IA; Flatt PR
    Diabetologia; 2013 Jun; 56(6):1425-35. PubMed ID: 23462797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.
    McClean PL; Irwin N; Hunter K; Gault VA; Flatt PR
    Br J Pharmacol; 2008 Nov; 155(5):690-701. PubMed ID: 18695644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
    Gault VA; Kerr BD; Irwin N; Flatt PR
    Biochem Pharmacol; 2008 Jun; 75(12):2325-33. PubMed ID: 18455149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Gastrin Family Peptides in Pancreatic Islets and Their Role in β-Cell Function and Survival.
    Khan D; Vasu S; Moffett RC; Irwin N; Flatt PR
    Pancreas; 2018 Feb; 47(2):190-199. PubMed ID: 29329158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.
    Irwin N; Franklin ZJ; O'Harte FP
    Eur J Pharmacol; 2013 Jun; 709(1-3):43-51. PubMed ID: 23562625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
    Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
    Parthsarathy V; Irwin N; Hasib A; Martin CM; McClean S; Bhat VK; Ng MT; Flatt PR; Gault VA
    Biochim Biophys Acta; 2016 Apr; 1860(4):757-64. PubMed ID: 26802310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of tolerance development with long-term administration of PEGylated cholecystokinin.
    Verbaeys I; León-Tamariz F; Buyse J; Decuypere E; Pottel H; Cokelaere M
    Peptides; 2009 Apr; 30(4):699-704. PubMed ID: 19084041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
    Martin CM; Irwin N; Flatt PR; Gault VA
    Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.